# Revisiting the Role of Tolvaptan in the Management of Hyponatraemia in Acute Heart Failure: Balancing Quality of Life and Cost With Tolvaptan Treatment

## TL;DR

This paper reviews how tolvaptan can help manage hyponatraemia in heart failure patients by improving quality of life and reducing hospital stays, while considering its cost and safety.

## Contribution

The paper provides a balanced evaluation of tolvaptan's role in heart failure with hyponatraemia, emphasizing quality of life and cost-effectiveness.

## Key findings

- Tolvaptan can increase serum sodium and reduce diuretic doses in heart failure patients.
- It may reduce hospitalisation duration and improve quality of life for selected patients.
- Long-term safety and cost-effectiveness of tolvaptan remain uncertain and require further study.

## Abstract

Hyponatraemia is a poor prognostic index in heart failure. It is a common complication of heart failure, associated with poorer outcomes including prolonged hospitalisation, increased morbidity, and reduced quality of life. For patients who have already developed this complication, the focus should be on improving their quality of life. The conventional management of hyponatraemia in heart failure largely depends on the cause and usually involves the intensification of the anti-heart failure regimen. For patients with severe hyponatraemia, it could mean an extra week's stay in the hospital on average or even longer, resulting in an increased rate of complications associated with prolonged hospitalisation. This not only increases healthcare costs but also exposes patients, particularly older adults, to risks related to immobility and hospital-acquired infections.

In theory, tolvaptan could bridge this gap in selected patients to reduce hospitalisation and improve quality of life. Tolvaptan is a selective vasopressin V2 receptor antagonist. Arginine vasopressin (AVP) plays a significant role in the pathophysiology of heart failure. It inhibits the action of AVP on renal collecting ducts, promoting free water excretion. Tolvaptan increases serum sodium and reduces diuretic doses. While it has not been associated with increased mortality, evidence on morbidity and long-term outcomes remains inconsistent. In addition, high cost and safety concerns restrict its widespread use.

This review highlights the role of tolvaptan beyond biochemical correction, with a focus on its potential to improve quality of life, reduce hospitalisations, and provide cost-effective benefits in carefully selected heart failure patients with hyponatraemia. By addressing these broader clinical and economic considerations, we provide a more balanced framework for evaluating its place in therapy. Nonetheless, further large, randomised controlled trials are required to confirm its long-term safety, cost-effectiveness, and overall impact on outcomes in this population.